Flotation

Xilio Therapeutics tunes into $118m IPO
Takeda, Merck & Co, Ipsen and Merck Group all scored exits as the immuno-oncology drug developer floated at the bottom of its IPO range.
Q4 reaches the front of IPO queue
The market communicationns platform developer is going public today in an $81m initial public offering which will enable OpenText to exit.
Abbisko nabs $226m in IPO
AstraZeneca, Eli Lilly and Sinopharm all achieved exits as the cancer therapy developer listed on the Hong Kong Stock Exchange at a reported valuation of nearly $1.1bn.
Pyxis progresses to stock market
Bayer, Pfizer and Ipsen-backed cancer therapeutics developer Pyxis Oncology priced its shares at the top of its range.
Exscientia expands IPO to over $350m
The cancer drug developer has closed an initial public offering which took place alongside a $160m SoftBank-led private placement.
Safie seals public listing
Canon, Kansai Electric Power, Mitsui Fudosan, NEC, NTT Docomo, So-net and T-Gaia were among the investors that scored exits as the CCTV system provider went public.
Exscientia establishes Nasdaq listing
SoftBank invested $125m through a $160m private placement as portfolio company and cancer drug developer Exscientia went public in an offering sized at nearly $305m.
Oxford Nanopore fetches $478m in IPO
Tencent, Nikon, Amgen and Illumina all scored exits as the DNA sequencing provider's shares popped in the wake of its flotation.

Other News

Warby Parker wraps up direct listing
The American Express-backed eyewear retailer's market capitalisation exceeded $6.1bn in the wake of its direct listing on the New York Stock Exchange.
Toast tops off $1bn initial public offering
The GV-backed restaurant organisation platform developer has issued $130m in additional shares to close its IPO and has a market capitalisation above $28bn.
Broncus broadcasts $215m IPO news
The Baidu Capital and Intuitive Surgical-backed lung disease-focused medical devices developer’s Hong Kong offering valued it at about $1.3bn.
Cue Health counts up $200m in IPO
The Johnson and Johnson, Dentsu and Koch Industries-backed diagnostics device developer priced its initial public offering in the middle of its range.
Remitly rakes in $523m in IPO
Prosus, Visa, and Prudential Financial scored exits as Remitly went public, with Prudential divesting $32.5m of shares through the offering.
Freshworks' IPO tops $1bn
Alphabet-backed CRM software provider Freshworks floated above its range and now boasts a market cap of $13.5bn.

Editor's Picks

Abbisko nabs $226m in IPO
AstraZeneca, Eli Lilly and Sinopharm all achieved exits as the cancer therapy developer listed on the Hong Kong Stock Exchange at a reported valuation of nearly $1.1bn.
Toast tops off $1bn initial public offering
The GV-backed restaurant organisation platform developer has issued $130m in additional shares to close its IPO and has a market capitalisation above $28bn.
Remitly rakes in $523m in IPO
Prosus, Visa, and Prudential Financial scored exits as Remitly went public, with Prudential divesting $32.5m of shares through the offering.
Freshworks' IPO tops $1bn
Alphabet-backed CRM software provider Freshworks floated above its range and now boasts a market cap of $13.5bn.
test reg

Login

Not yet subscribed?

See your subscription offers here